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Introduction
Candida spp. are normal yeast flora commensally present 
on the mucosal surfaces of about 60%-80% of healthy in-
dividuals (1). But in the case of impaired or suppressed 
immunity, Candida spp. could trigger the opportunistic 
fungal infections in spite of their nonpathogenic nature 
(2). Factors affecting immune system such as diabetes, 
long-term corticosteroid therapy, receiving solid-organ 
transplants, immunosuppressing diseases such as HIV 
and neutropenia might predispose the patients to fungal 
infections which are usually known as nosocomial fungal 
infections (3).
Intrinsic and acquired multi-drug antimicrobial resistance 
of fungi in immunocompromised patients has been fre-
quently reported as an important medical issue in recent 
years (4). Candida (formerly Torulopsis) glabrata was re-
corded as the second leading cause of invasive candidiasis 
(IC) in immunosuppressed patients in the United States 
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Introduction: Candida glabrata is a yeast fungus regularly isolated from patients with impaired 
immunity who receive a routine antifungal therapy. Drug-resistant strains of C. glabrata have been 
emerged in recent years. The aim of this study was to examine the therapeutic efficacy Origanum 
vulgare essential oil (OVEO) against drug-resistant strains of C. glabrata and its cytotoxic effect 
on macrophages.
Methods: Specimens were collected from mucosal surfaces of the oral cavity of medically approved 
oropharyngeal candidiasis (OPC) in HIV-positive patients and volunteered healthy individuals 
using sterile swabs or mouthwashes. In vitro antifungal susceptibility testing was done using 
microdilution and disc diffusion methods. Chemical composition of OVEO was determined using 
gas chromatography mass spectrometry. The cytotoxic effect of essential oil on macrophages was 
examined using tetrazolium dye (MTT).
Results: Minimum inhibitory concentration (MIC) range of OVEO in healthy individuals and 
OPC patients was 150-200 and 150-250 µg/mL, respectively. OVEO efficiently inhibited growth of 
resistant isolates. In isolates obtained from HIV patients, both MIC50 and MIC90 of OVEO were 
200 µg/mL while in healthy individuals were 150 and 200 µg/mL, respectively. Moreover, OVEO 
induced significant reduction in proliferation of murine RAW264.7 and peritoneal macrophages 
in concentrations higher than 100 and 300 µg/mL, respectively. Main constituents of OVEO were 
thymol (27.3%), γ-terpinene (20.7%) and carvacrol (16.1%).
Conclusion: OVEO could be used as a fungicidal agent against fungal infections caused by azole-
resistant C. glabrata. A combination therapy along with standard antifungals is suggested to avoid 
its cytotoxic effects.
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(5). Most of the C. glabrata infections occurred on mu-
cosal surfaces (oral cavity, esophagus, vagina, or urinary 
system) or as a systemic blood stream infection (6). At 
least one episode of vulvovaginal candidiasis is observed 
in 75% of all women during lifetime, and 5%-10% of 
whom will acquire the disease again (7). Azole-resistance 
of C. glabrata and Candida krusei isolates in recurrent 
vulvovaginal candidiasis (RVVC) patients has been docu-
mented (8). The frequency of itraconazole-resistant C. 
glabrata isolates was reported 74.1% in RVVC patients (8).
In recent years alternative nature-based therapies have 
been taken into consideration. Origanum species are one 
of the local medicinal plants growing wild in and endemic 
to Mediterranean countries. Most of the Origanum spe-
cies grow in east Mediterranean regions. Unlike most 
Origanum species, Origanum vulgare is the only species 
widely spread in different regions and commonly occurs 
in the Irano-Turanian region (9). The blooming period of 
endemic O. vulgare species in Iran is between June and 
August. It grows in different geographical regions in Iran, 
mostly in west, northwest and north (10).
The main purpose of the present study is to examine po-
tential antifungal attributes of essential oil (EO) of endem-
ic Iranian O. vulgare and to determine its cytotoxic effect 
on a murine RAW264.7 macrophage cell line and murine 
peritoneal macrophages. We compared the EO fungicid-
al activity among C. glabrata isolates obtained from two 
groups of volunteers including healthy individuals and 
HIV-positive patients with oropharyngeal candidiasis 
(OPC) clinical manifestations.
Materials and methods
Plant materials and isolation of EO
Origanum vulgare Linn. ssp. vulgare in pre-flowering stage 
in June 2014 was collected from forests and highlands 
around Piranshahr, West Azarbaijan province, northwest 
Iran. The plant was authenticated by a herbal specialist. 
250 g of ground aerial parts of plant was mixed in 1600 mL 
of distilled water and transferred into a Clevenger appara-
tus. The EO isolation was done by hydrodistillation for 3 
hours according to instructions recommended by British 
pharmacopoeia. Water was removed from extracted EO 
by decantation and anhydrous sodium sulphate. Density 
of purified EO was obtained 0.92 g/mL by gravimetric 
method. Isolated purified EO was stored at 4°C in a dark 
container until use.
Characterization of EO chemical composition
Chemical composition of O. vulgare EO (OVEO) was 
determined by gas chromatography (GC)-flame ioniza-
tion detector (FID) and GC-mass spectrometry (MS). A 
Thermoquest Finnigan (later Thermo Fisher Scientific) 
instrument equipped with a DB-5 capillary column (60 m 
× 0.25 m i.d., film thickness 0.25 µm) was used for GC-
FID. Nitrogen was used as carrier gas at a fixed flowing 
rate of 1.1 mL/min. The ionization energy was 70 eV in a 
split mode (ratio 1:50). The oven temperature was gradu-
ally elevated from 60°C to 250°C at a rate of 5°C/min. The 
injector and detector (FID) temperature was set at 250°C 
and 280°C, respectively. GC-MC evaluation of OVEO was 
established using a Thermoquest Finnigan Trace GC-MS 
machine. The temperature program and capillary column 
used in this analysis were the same as GC-FID. Helium 
at a flowing rate of 1.1 mL/min was used for GC-MS in a 
split ratio of 1:50. The main components present in OVEO 
were characterized by measuring their retention indices 
resulted from programmed temperatures for n-alkanes 
(C6-C24) and capillary column. The components were 
detected by comparing their mass spectra to the inter-
nal reference mass spectra database in software provided 
alongside GC instrument. Quantification of identified 
components was obtained by calculating the area under 
the FID peaks.
Specimen collection from human participants
Before specimen collection, all participants received in-
formed consent. All HIV positive patients included in 
this study had clinical manifestations of OPC and had re-
ceived azole therapy. Also, healthy volunteers who had no 
history of receiving azole drugs were classified eligible to 
participate in the study. Samples were collected from oral 
mucosal surfaces using sterile swabs. Number, grouping 
and demographic characteristics of HIV-positive patients 
and healthy volunteers under this study can be found in 
our two previous studies (11,12). For some of the OPC pa-
tients, we used mouthwash (MW) method.
Yeasts growth conditions and identification
The swabs and MW samples were cultured on Sabouraud 
Dextrose Agar and incubated aerobically at 37°C for 72 
hours. Yeast isolates were identified using morphologic, 
physiologic, biochemical and molecular methods.
In-vitro susceptibility testing – microdilution
Broth microdilution antifungal susceptibility testing 
(AST) for yeasts was done for yeasts based on National 
Committee for Clinical Laboratory Standards (NCCLS) 
(recently referred to as Clinical and Laboratory Standards 
Institute [CLSI]) M27-A2 protocol (13). OVEO along 
with two azole derivatives including fluconazole and itra-
conazole were incorporated in AST. OVEO dilutions were 
prepared in MOPS-buffered RPMI1640 medium contain-
ing 4% ethanol. Final concentrations of OVEO in yeast-
inoculated wells were 10, 20, 50, 100, 150, 200, 250, 300, 
400 and 500 µg/mL. Final concentration of ethanol was 
2%. Concentration of OVEO solutions in ethanol was cal-
culated based on density of OVEO which was 0.92 g/mL 
and density of ethanol which was 0.79-0.793 g/cm3 (mean 
0.7915 g/cm3). Also, both fluconazole and itraconazole 
were dissolved in DMSO. The concentration range of two-
fold solutions for fluconazole and itraconazole was 0.25-
128 µg/mL and 0.0625-32 µg/mL, respectively. Final con-
centration of DMSO was 1% based on M27-A2 instruc-
tions (13). Inoculated microtiter plates were incubated at 
35°C for 24 and 48 hours. MIC end points were read at 24 
and 48 hours.
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In vitro susceptibility testing-disc diffusion
Neo-Sensitabs™ fluconazole 25 µg tablets were used for 
antifungal disk diffusion susceptibility testing of yeasts 
based on CLSI M44-A protocol (14). Zone of inhibition 
was defined as the nearest whole millimeter at the point at 
which there was a prominent decrease in growth of yeast 
colonies around drug disc.
Macrophage cell culture conditions
Murine peritoneal RAW264.7 macrophage (RM) cell line 
was purchased from Human and Animal Cell Bank, Ira-
nian Biological Resource Center. Cells were cultured us-
ing high glucose DMEM with 10% FBS and incubated in 
a humidified 5% CO2 incubator at 37°C. Eight-week-old 
female BALB/c mice were purchased from Razi Vaccine 
and Serum Research Institute, Tehran, Iran. Murine nor-
mal resident peritoneal macrophages (PMs) were isolated 
from peritoneal cavity of the mice and were cultured in 
DMEM supplemented with 10% FBS.
MTT cytotoxicity assay
RPMI 1640 medium without phenol red (RWP) was used 
for MTT assay. 104 cells in 100 µL of RWP medium were 
seeded into each well of 96-well microtiter plate. Final 
concentrations of OVEO in 10 wells of a row were 10, 100, 
150, 200, 250, 300, 350, 400, 500, 1000 µg/mL. Triton-
X100 was used as positive control. Last well was dispensed 
by only 100 µL of RWP medium (negative control). After 
24-hour incubation the supernatant was removed and 100 
µL of fresh RWP medium was replaced. 10 µL of 5 mg/
mL MTT stock solution was added to each well. The plate 
was incubated at 37°C for 4 hours. After 4-hour incuba-
tion, the supernatant medium was gently aspirated out 
and 100 µL of DMSO was dispensed into each well and 
mixed thoroughly by pipetting. The plate was incubated 
at 37°C for 15 minutes. All wells were mixed thoroughly 
and the absorbance was read using an ELISA reader at 570 
nm wavelength. 
Statistical analysis
Mann-Whitney U test was used to investigate the differ-
ences in mean MIC of OVEO between two groups. Also 
we analyzed the differences between frequencies of resist-
ant, susceptible and susceptible dose-dependent (SDD) 
isolates using the test of proportions. Inhibitory concen-
trations 50% (IC50) of OVEO were calculated using dose-
response analysis and three-parametric nonlinear regres-
sion method. P values less than 0.05 were considered as 
significant.
Results
Monoterpenes and oxygenated monoterpenes were main 
components of OVEO 
Main components of OVEO according to GC-FID and GC-
MS analysis were thymol (27.3%), γ-terpinene (20.7%), 
carvacrol (16.1%), germacrene D-4-ol (9.5%), β-Pinene 
(6.4%), β-caryophyllene (3.2%) and p-cymene (3%). Oxy-
genated monoterpenes including cis-β-terpineol (1.3%), 
thymol (27.3%) and carvacrol (16.1%) were main group 
of components in OVEO. Two phenolic isomers thymol 
(27.3%) and carvacrol (16.1%) comprised 43.4% of OVEO 
as most abundant components followed by monoterpene 
hydrocarbons including α-thujene, α-pinene, sabinene, 
β-pinene, α-terpinene, γ-terpinene and p-cymene com-
prising 35.4% of OVEO and oxygenated sesquiterpenes 
including germacrene D-4-ol and caryophyllene oxide. 
Sesquiterpene hydrocarbons including β-caryophyllene, 
α-himachalene and α-candinene were other components 
of OVEO. Octen-3-ol (0.3%), an aromatic alcohol, was 
also detected in OVEO (Table 1).
Azole-resistant isolates of C. glabrata were more prevalent 
among patients with OPC
We could isolate six C. glabrata isolates from individu-
als people and 16 isolates from patients with OPC. All 
C. glabrata isolates obtained from healthy individuals 
were classified as susceptible based on fluconazole and 
itraconazole disc diffusion and microdilution test results 
(Table 2 and Figure 1). The results of fluconazole disc 
diffusion and fluconazole microdilution tests in isolates 
from healthy people were 100% identical (all isolates were 
classified susceptible by both methods). Also in the case 
of isolates from patients with OPC, only two differences 
were observed between the results of fluconazole disc dif-
fusion and fluconazole microdilution. These two isolates 
were susceptible in fluconazole disc diffusion but were 
SDD in fluconazole microdilution. On the other hand, 
among isolates obtained from patients with OPC, 10 iso-
lates in both fluconazole microdilution and disc diffusion 
Table 1. Chemical composition of Origanum vulgare essential oil by 
GC-MS and GC-FID analysis
Components RI Area under peak (%)
α-Thujene 932 0.9
α-Pinene 943 1.3
Octen-3-ol 975 0.3
Sabinene 984 1.3
β-Pinene 988 6.4
α-Terpinene 1026 1.8
p-Cymene 1035 3
γ-Terpinene 1060 20.7
cis-β-Terpineol 1153 1.3
Thymol 1285 27.3
Carvacrol 1288 16.1
β-Caryophyllene 1380 3.2
α-Himachalene 1459 2.2
Germacrene D-4-ol 1493 9.5
α-Candinene 1531 1
Caryophyllene oxide 1582 2.8
Total 99.1
Monoterpene hydrocarbons 35.4
Oxygenated monoterpenes 44.7
Sesquiterpene hydrocarbons 6.4
Oxygenated sesquiterpenes 12.3
Others 0.3
Abbreviations: GC-MS, gas chromatography mass spectrometry; GC-
FID, gas chromatography-flame ionization detector; RI, retention index.
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assays were classified as resistant in order to CLSI instruc-
tions (Table 2 and Figure 1). The frequencies of resistant 
isolates based on disc diffusion and micro dilution tests 
in patients with OPC were statistically higher than those 
in healthy individuals (P = 0.0322, test of proportions). In 
addition, four isolates obtained from patients with OPC 
showed resistant properties in itraconazole microdilution 
AST. Four other isolates were SDD in itraconazole AST 
(Table 2). There was not any significant difference in itra-
conazole results between resistant isolates from healthy 
individuals and patients with OPC (P = 0.4633, test of 
proportions). MIC50, MIC90 and MIC ranges of azole 
drugs in C. glabrata isolates obtained from patients with 
OPC were considerably higher than those obtained from 
healthy individuals (Table 2).
OVEO completely inhibits growth of both resistant and 
non-resistant isolates of C. glabrata
The MIC of OVEO for C. glabrata isolates obtained from 
healthy individuals ranged 150-200 µg/mL. Also the MIC 
range for isolates from OPC patients was 150-250 µg/mL 
(Table 2). No statistically significant difference was found 
between the mean MIC of isolates from healthy people 
and mean MIC of isolates from OPC cases (P = 0.0809, 
Mann-Whitney U test). Also, the difference between the 
mean OVEO MIC of azole- resistant and non-resistant 
isolates obtained from OPC patients was not significant 
(P = 0.0873, Mann-Whitney U test). However, MIC of 
OVEO in azole-resistant isolates of C. glabrata among 
OPC patients was slightly higher than those in azole- sus-
ceptible and -SDD isolates in both patients with OPC and 
healthy individuals.
OVEO exhibits its cytotoxic activity on RMs and PMs 
in concentrations higher than 100 and 300 µg/mL, 
respectively
Both macrophage cell types (cell line and normal cells) 
showed a descending pattern of proliferation rate in re-
sponse to increasing dose of OVEO (Figure 2). Prolifera-
tion rate of murine RMs and PMs was significantly lower 
than negative control cells at concentrations 150 and 350 
µg/mL of OVEO, respectively (P = 0.0215 and P = 0.008, 
respectively, Mann-Whitney U test). The significant re-
duction in proliferation of cells continued in all subse-
quent higher concentrations (Figure 2). IC50 of OVEO 
for RMs was 346.6 µg/mL while the IC50 of OVEO for 
PMs was calculated 630.4 µg/mL using a three-parametric 
nonlinear regression model. Moreover, the morphology 
of macrophages was affected by OVEO treatment. Mac-
rophages treated with toxic doses of OVEO seemed to 
be detached from surface of the culture flask, floated and 
rounded (Figure 3).
Discussion
We have studied the chemical composition of OVEO us-
ing chemical analysis instruments. We found the follow-
ing components in order of amount; thymol, γ-terpinene 
and carvacrol, as the most abundant in OVEO. Our find-
ings are partially consistent with the only study of OVEO 
in the same geographical region (10).
Long-term azole administration for treatment of oral 
candidiasis in HIV patients could result in emergence of 
azole resistance. 81% of non-C. albicans isolates in azole-
administered patients were fluconazole-resistant (15). 
These reports are in agreement with our results. We have 
found that 81.25% (13/16) of C. glabrata isolates obtained 
from patients with OPC were fluconazole- resistant or 
Table 2. MIC ranges, MIC50 and MIC90 of azoles and Origanum vulgare essential oil and frequencies of azole-resistance in Candida glabrata 
isolates obtained from healthy individuals and OPC patients
Participants Antifungals
MIC (µg/mL) R 
No. (%)
SDD 
No. (%)
S 
No. (%)50 (%) 90 (%) Range
Healthy
Fluconazole 1 2 0.5-4 0 (0 %) 0 (0 %) 6 (100 %)
Itraconazole 0.03125 0.0625 0.03125-0.0625 0 (0 %) 0 (0 %) 6 (100 %)
OVEO 150 200 150-200 - - -
Patients with OPC
Fluconazole 64 64 4-64 10 (62.5 %) 3 (18.75 %) 3 (18.75 %)
Itraconazole 0.125 1 0.0625-4 4 (25 %) 4 (25 %) 8 (50 %)
OVEO 200 200 150-250 - - -
Abbreviations: MIC, minimum inhibitory concentration; OPC, oropharyngeal candidiasis; No, number; R, resistant; SDD, susceptible dose-dependent; 
S, susceptible.
Figure 1. Antifungal susceptibility testing of Candida glabrata 
isolates by disc diffusion; fluconazole 25 µg tablets were used 
for disc diffusion assays; (A) disc diffusion testing of an azole-
resistant isolate of a C. glabrata obtained from a patient with 
oropharyngeal candidiasis (OPC); (B) disc diffusion testing of a 
C. glabrata isolated from a healthy individual; (C) disc diffusion 
testing of a standard strain of C. glabrata (ATCC 90030); (D) 
disc diffusion testing of a blank disc on the standard strain of C. 
glabrata (ATCC 90030).
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-SDD. Ten of 16 (62.5%) isolates were fluconazole-resist-
ant and four (25%) were itraconazole-resistant. Moreover, 
the researchers observed that in none-immunosuppressed 
patients, only 1.2% and 0.9% of C. albicans isolates were 
fluconazole- and itraconazole- resistant, respectively. This 
means that approximately all C. albicans isolates obtained 
from immunocompetent/healthy individuals were azole-
susceptible. But among C. glabrata isolates, 7% and 19.5% 
of isolates were resistant to fluconazole and itraconazole, 
respectively (16). This means that some of the C. glabrata 
isolates obtained from immunocompetent/healthy indi-
viduals were again azole-susceptible even if their hosts 
did not receive any azole-therapy regimen during lifetime. 
This finding could represent intrinsic-resistance to azoles 
in C. glabrata isolates obtained from healthy people. But, 
in our study, all isolates from healthy individuals were 
azole-susceptible. No resistance among the isolates from 
healthy individuals in the present study could be due to 
inclusion of a small population of healthy individuals in 
AST examinations.
The antimicrobial activity of EO constituents was ranked 
as follows: phenols > aldehydes > ketones > alcohols > 
esters > hydrocarbons (17). Thymol and carvacrol are 
phenolic monoterpenes. The mixture of thymol and car-
vacrol results in stronger antimicrobial activity (18). Also, 
γ-terpinene is a monoterpene hydrocarbon that has no 
considerable antibacterial or fungicidal activity (19). There 
has been only one study of antifungal efficacy of EO of an 
Iranian strain of O. vulgare against fluconazole-resistant 
and susceptible isolates of C. glabrata to date. But in con-
trast to our study the C. glabrata isolates in the referenced 
study were obtained from patients with vulvovaginal can-
didiasis and the mean MIC of OVEO on C. glabrata iso-
lates was 340.2 µg/mL. The main components of O. vul-
gare strain in referenced study were linalool (42%), thy-
mol (25.1%) and α-terpineol (10%) (20). A recent similar 
study has incorporated fluconazole-resistant and suscep-
tible isolates of C. glabrata but C. glabrata isolates used in 
this study were not clinical and the fluconazole resistance 
was induced in vitro (21). Mean MIC and minimum fun-
gicidal concentration for two fluconazole-susceptible and 
-resistant groups of C. glabrata isolates were significantly 
different (21). Our MIC results for fluconazole-resistant 
C. glabrata isolates were inconsistent with the referenced 
study. Also, in a similar study Candida yeast species were 
isolated either from OPC patients or immunocompro-
mised patients with disseminated mycoses (22). The MIC 
range for both fluconazole-resistant and susceptible iso-
lates of C. albicans was 200-800 µg/mL. The MIC90 for 
all fluconazole-resistant and susceptible subgroups of C. 
albicans and Candida dubliniensis isolates was 400 µg/mL. 
There was no difference in MIC ranges between resistant 
and susceptible isolates of Candida species (22). In our 
study, there was also no difference in OVEO MIC90 val-
ues between resistant and susceptible isolates but the MIC 
values of C. glabrata isolates were different from those in 
the referenced study. These variations might be explained 
by different EO chemical composition of Oregano strains 
used in these investigations. In the referenced study, car-
vacrol comprised 92.6% of OVEO (21,22). But in our 
study thymol and carvacrol together comprised 43.4% of 
OVEO with a thymol/carvacrol ratio of 1.7. The differ-
ences in MIC values between our study and other studies 
may relate to the reported evidences on the synergism be-
tween thymol and carvacrol. Combination of thymol and 
carvacrol has further antimicrobial activity (23). The best 
antimicrobial synergy was obtained in thymol and carvac-
rol ratio of 1:1 (23).
Thymol and carvacrol mode of action has been mostly 
related to their reaction with microbial cell membrane. 
They initiate modifying effects on the outer and inner 
membrane, interact with or misfold/unfold the outer 
membrane proteins, cause changes in cell membrane flu-
idity, increase the membrane permeability and leakage of 
Figure 2. Antiproliferative effect of Origanum vulgare essential oil 
(OVED) on two types of murine macrophages including RAW264.7 
and resident peritoneal macrophages. Cells were treated with 
different concentrations of O. vulgare essential oil for 24 hours 
then the percentage of cell growth inhibition was measured by 
MTT assay. + indicates significant difference in inhibition rate 
of cells proliferation between the cells treated with O. vulgare 
essential oil and negative control cells (P < 0.05, Mann-Whitney 
U test). X indicates significant difference in inhibition rate of cells 
proliferation between the cells treated with O. vulgare essential oil 
and negative control cells (P < 0.05, Mann-Whitney U test).
Figure 3. RAW264.7 macrophages (RMs) were imaged using 
an inverted microscope; (A) the negative control RMs after 24-
hour incubation where most of the macrophages show normal 
morphology, are stretched and usually adhered; (B) RMs treated 
with 300 µg/mL Origanum vulgare essential oil (OVED) after 24-
hour incubation; The upper arrow points to detached, floated, 
clumped and rounded RMs; lower arrow points to adhered and 
stretched RMs.
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necessary ions and change the pH hemostasis (24). The 
mechanisms of their antifungal action have been related 
to disruption of the fungal cell wall integrity and weak-
ening of the synthesis procedure of ergosterol (25). Mu-
tations or alterations of enzymes have been involved er-
gosterol biosynthesis pathways, which are the targets of 
azole drugs, and fungal cell adaptation to azole drugs by 
regulating the efflux pumps has been known to be respon-
sible for developing azole resistance in Candida spp. (26). 
The ergosterol-impairing effect of thymol and carvacrol 
indicates the potential synergistic activity of these natural 
antifungals with the standard ergosterol synthesis-target-
ing antifungal agents like azoles (27). In addition, the cell 
wall-disrupting action of thymol and carvacrol seems to 
possess a potential synergistic activity with well-known 
cell wall-disrupting activity of the polyenes including am-
photericin B and nystatin (28).
To the best of our knowledge, only two studies have inves-
tigated the cytotoxic effect of OVEO, carvacrol or thymol 
on macrophages or peritoneal leukocytes (29,30). In one 
of these studies, human THP-1 macrophage cell line and 
human peripheral blood mononuclear cells (PBMCs) were 
treated with Origanum syriacum L. and Thymus vulgaris 
L. extracts. IC50 values of O. syriacum extract on THP-1 
cells and PBMCs were 2126 and 425 µg/mL, respectively. 
The toxic effect of O. syriacum extract on normal PBMCs 
was significantly higher than that on THP-1 cell line (29). 
Our examinations of normal macrophages and cell line 
macrophages showed that the toxic effect of OVEO on cell 
line macrophages was about two times higher than that 
on normal macrophages. But we have used EO of a local 
strain of O. vulgare and the origin of both cell types were 
from mice. In a study, the toxic effect of Thymus vulgaris 
EO and its main components, thymol and carvacrol, was 
investigated on leukocytes isolated from peritoneal cavity 
of rats. T. vulgaris EO showed considerable reduction in 
cell viability at concentration ≥90 µg/mL. For carvacrol, 
the cell viability did not change at concentration as high as 
90 μg/mL. In thymol MTT assay, no reduction in cell vi-
ability was observed at all concentrations, even 150 μg/mL 
(30). No reported toxicity of thymol and carvacrol men-
tioned in previous studies is consistent with our results. 
In our study, the main components of OVEO were phe-
nolic monoterpenes including thymol and carvacrol and 
the significant reduction in viability of RMs and PMs was 
started at concentrations 150 and 350 μg/mL of OVEO, 
respectively.
Conclusion
In our experiments, OVEO showed fungicidal activ-
ity against both azole-resistant and non-azole-resistant 
strains of C. glabrata and also showed toxic effect against 
macrophages. Although its IC50 values (on both mac-
rophage cell types) were higher than its fungicidal doses, 
but to gain a safe result we suggest a combination therapy 
of standard antifungal drugs such as Amphotericin B, 
azoles and nystatin whose mechanism(s) of action is (are) 
the same as and/or similar to those of OVEO and therefore 
prevent or ameliorate the cytotoxic and adverse effects of 
both standard drugs and any OVEO-based therapies.
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